Abstract: The invention provides a parathyroid hormone (PTH) compound comprising a PTH peptide. The PTH compound has a significantly increased bioavailability or circulating half-life when compared to a bioavailability or a circulating half-life of a native form of the PTH peptide. The PTH compound has a significantly greater serum concentration at multiple timepoints post-administration to a rat when compared to that of a native PTH peptide.
Type:
Grant
Filed:
January 29, 2019
Date of Patent:
September 14, 2021
Assignee:
Extend Biosciences, Inc.
Inventors:
Tarik Soliman, Laura M. Hales, Daniel B. Hall, Christopher So, Howard P. Sard, Vishnumurthy Hegde
Abstract: This invention relates to materials, such as peptides, and methods to inhibit the aggregation transcription factors, for example p53 inhibitors, p63 inhibitors and p73 inhibitors. More specifically, the invention relates to cancer chemotherapeutics. More specifically, the invention provides pharmaceutical compositions and methods of treating cancer with certain peptides.
Type:
Grant
Filed:
February 23, 2018
Date of Patent:
September 14, 2021
Assignee:
ADRX, INC.
Inventors:
Shiho Tanaka, Ashley Wright, James Treanor, Marcin Apostol
Abstract: Provided herein are compositions and methods for treating and preventing lung disease. In particular, provided herein are SP-A peptides and uses thereof in the treatment and prevention of lung disease (e.g., asthma or COPD).
Type:
Grant
Filed:
April 11, 2017
Date of Patent:
September 7, 2021
Assignee:
ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA
Abstract: The present disclosure describes a new native peptide designated herein as Dwarf Open Reading Frame, or DWORF. This peptide enhances the apparent activity of the SERCA pump, is positively inotropic and lusitropic, and therefore is provided as a therapeutic agent for disorders characterized by cytosolic calcium overload.
Type:
Grant
Filed:
January 15, 2020
Date of Patent:
September 7, 2021
Assignee:
The Board of Regents of the University of Texas System
Inventors:
Eric N. Olson, Rhonda S. Bassel-Duby, Catherine A. Makarewich, Benjamin R. Nelson
Abstract: The invention relates to peptide dimer compounds and peptide monomer compounds that potently inhibit binding of ?4?7 to the mucosal addressin cell adhesion molecule (MAdCAM) in vivo, possess high selectivity against ?4?1 binding, and have high stability under gastrointestinal conditions.
Type:
Grant
Filed:
February 4, 2020
Date of Patent:
September 7, 2021
Assignee:
Protagonist Therapeutics, Inc.
Inventors:
Ashok Bhandari, Dinesh V. Patel, Genet Zemede, Larry C. Mattheakis, David Liu
Abstract: Provided are methods for prophylaxis and/or therapy for Phelan-McDermid Syndrome (PMS) and autism spectrum disorder (ASD). The methods involve administering a histone methyltransferase (HMT) inhibitor, a histone deacetylase (HDAC) inhibitor, or a combination thereof, such that one or more symptoms of the PMS and/or the AMD are reduced.
Abstract: A biologically active complex comprising a polypeptide having the sequence of a naturally occurring protein or a variant thereof, wherein said polypeptide is at least partially unfolded as compared to the said naturally occurring protein for example as a result of a modification of at least one cysteine residue; or a peptide of up to 50 amino acids; and a fatty acid or lipid or a salt thereof, for use in prophylactic treatment of cancers, in particular of the gastrointestinal tract. Compositions that may comprise the complex and have use as nutraceuticals are obtainable from milk or milk fractions and form a further aspect of the invention. Methods of treatment in particular for the prevention of cancer form a further aspect of the invention.
Type:
Grant
Filed:
August 8, 2013
Date of Patent:
August 31, 2021
Assignee:
Hamlet Pharma AB
Inventors:
Catharina Svanborg, Manoj Puthia, Chin Shing Ho
Abstract: The present invention relates to a novel exenatide analogue, which is an exenatide analogue in which the first to fifteenth amino acids from the C-terminal of the amino acid sequence of exenatide are deleted and a fatty acid is conjugated. The present invention provides a short length exenatide exhibiting almost the same level of anti-diabetic effects compared with that of conventional exenatide and liraglutide, which is an anti-diabetic drug, and capable of reducing the preparation cost of exenatide.
Type:
Grant
Filed:
March 23, 2015
Date of Patent:
August 31, 2021
Assignee:
ANYGEN Co., Ltd.
Inventors:
San Ho Kim, Seon Myung Kim, Moon Young Park
Abstract: The present invention provides a polyethylene glycol-modified endostatin analogue and an application thereof. The endostatin analogue is coupled to polyethylene glycol at lysine away from a nucleolin binding domain, or is coupled to polyethylene glycol at lysine away from a nucleolin binding domain and amidogen at the N end.
Abstract: Novel inhibitors of IAP that are useful as therapeutic agents for treating malignancies and have the general formula I: wherein R1, R2, R3, R4, R5 and R6 are as described herein.
Type:
Grant
Filed:
April 2, 2019
Date of Patent:
August 24, 2021
Assignee:
GENENTECH, INC.
Inventors:
Frederick Cohen, Lewis J. Gazzard, Vickie Hsiao-Wei Tsui, John A. Flygare
Abstract: The present invention has an object of providing a peptide synthesis method using a carrier capable of reversibly repeating the dissolved state and the insolubilized state, wherein the problem of an amino acid active species existing in the reaction system in de-protection reaction can be easily solved. The present invention provides a peptide synthesis method comprising the following steps: a step of condensing an N-Fmoc protected amino acid with a peptide having a C-terminal protected with a carrier which is crystallized according to a change of a composition of a dissolving solvent, in the presence of a condensing agent, to obtain an N-Fmoc-C-carrier protected peptide, a step of adding an alkylamine having 1 to 14 carbon atoms or hydroxyl amine to the reaction system, a step of de-protecting the N-terminal, and a step of changing the composition of the solvent dissolving the C-carrier protected peptide, to crystallize and separate the peptide.
Abstract: Disclosed are recombinant polypeptides that include (a) a filaggrin amino acid sequence and (b) a cell importation signal sequence that includes a motif of two to fifteen amino acids, wherein the motif includes at least one arginine residue and at least one methionine residue. Also disclosed are nucleic acids encoding the recombinant polypeptides of the present invention, and compositions that include the recombinant polypeptides and nucleic acids of the present invention. Methods of treating or preventing a skin disease or skin disorder using the compositions of the present invention are also included, as well as kits that include a sealed containing that includes a recombinant polypeptide of the present invention.
Type:
Grant
Filed:
January 8, 2019
Date of Patent:
August 24, 2021
Assignee:
Research Development Foundation
Inventors:
J. Timothy Stout, Binoy Appukuttan, Trevor McFarland
Abstract: Compositions and methods for controlling pests are provided. The methods involve transforming organisms with a nucleic acid sequence encoding an insecticidal protein. In particular, the nucleic acid sequences are useful for preparing plants and microorganisms that possess insecticidal activity. Thus, transformed bacteria, plants, plant cells, plant tissues and seeds are provided. Compositions are insecticidal nucleic acids and proteins of bacterial species. The sequences find use in the construction of expression vectors for subsequent transformation into organisms of interest, as probes for the isolation of other homologous (or partially homologous) genes. The insecticidal proteins find use in controlling, inhibiting growth or killing lepidopteran, coleopteran, dipteran, fungal, hemipteran, and nematode pest populations and for producing compositions with insecticidal activity.
Abstract: The present invention provides a Mitrecin A polypeptide useful in prevention and treatment of one or more bacteria. Also provided is a method to kill or prevent growth of one or more bacteria comprising contacting the one or more bacteria with a Mitrecin A polypeptide. The target bacteria can be selected from the group consisting of a Gram-positive bacterium, a Gram-negative bacterium, or both. In one embodiment, the present invention is drawn to a polynucleotide encoding a Mitrecin A polypeptide, a vector comprising the polynucleotide, a host cell comprising the polynucleotide, or a composition comprising the Mitrecin A polypeptide, the polynucleotide, the vector, or the host cell.
Abstract: Compositions comprising iron-sequestering glycoproteins, chelating agents, stabilizing agents, binding agents, surfactants, fluorides, antimicrobials and a pH adjuster or buffer for the prevention and treatment of oral cavity diseases caused by dental plaque/biofilm, such as dental caries, gingivitis and periodontitis, through anti-infective properties are disclosed. The anti-infective properties of a composition include reduction or killing of anaerobic/aerobic/facultative gram-negative and gram-positive oral bacteria occurring in polymicrobial dental biofilms. The composition may be in the form of wash, rinse, soak, paste, gel, spray, or other suitable form. Additionally, the invention offers an efficient method of delivering the formulated composition containing a PEGylated or fluorinated iron-sequestering glycoprotein and one or two chelating agents or chelating agents alone using either a liposomal or a nanoparticle delivery system.
Abstract: The present disclosure is generally directed to compositions and methods for treating or limiting development of vasomotor symptoms in a subject.
Type:
Grant
Filed:
August 28, 2018
Date of Patent:
August 10, 2021
Assignee:
University of Washington through its Center for Commercialization
Inventors:
Robert A. Steiner, Charles Chavkin, Donald K. Clifton, Susan Reed, Victor Navarro
Abstract: Disclosed are novel peptides comprising SEQ ID NO: 1 and modifications thereof, which are effective in blocking leukocyte recruitment. The disclosed peptides are useful for treating diseases associated with leukocyte recruitment for example inhibiting metastasis of a solid tumor to the liver and lungs and for treating sepsis. Also disclosed are methods of screening for compounds having the ability to block leukocyte recruitment.
Type:
Grant
Filed:
September 13, 2018
Date of Patent:
August 10, 2021
Assignee:
ARCH CANCER THERAPEUTICS, INC.
Inventors:
Stephen Mark Robbins, Donna Lorraine Senger, Jennifer Joy Rahn, Paul Kubes
Abstract: Disclosed are a conjugate including a mitochondria-targeting moiety and a peptide molecule capable of self-assembly; and a pharmaceutical composition for preventing or treating cancer including the conjugate as an active ingredient.
Type:
Grant
Filed:
November 15, 2017
Date of Patent:
August 10, 2021
Assignee:
Unist (Ulsan National Institute of Science and Technology)
Inventors:
Ja Hyoung Ryu, Manayath Thekkeyil Jeena
Abstract: De novo artificial protein based reporters that may be expressed in eukaryotic (e.g., mammalian) cells and methods of using the same are provided herein.
Type:
Grant
Filed:
November 4, 2016
Date of Patent:
August 10, 2021
Assignee:
THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
Inventors:
Goutham Kodali, Molly Marie Sheehan, Joshua Mancini, Bohdana Marie Discher, Michael Magaraci, Nathan M. Ennist, Brian Chow, Peter Leslie Dutton, Christopher Moser
Abstract: Provided are non-naturally occurring cystine knot peptides (CKPs) that bind to VEGF-A. Additionally, provided are methods of using non-naturally occurring CKPs that bind to VEGF-A, including diagnostic and therapeutic compositions and methods. Non-naturally CKPs that bind low density lipoprotein receptor-related protein 6 (LRP6) are also provided.